Core Viewpoint - The domestic beauty brand, HBN, is transitioning from a follower to a challenger in the market, capitalizing on the maturity of the Chinese supply chain and the benefits of social media, while facing challenges in maintaining growth as it approaches a saturation point in online channels [1][9]. Group 1: Company Overview - HBN, a core brand of Shenzhen Hujia Technology (Group) Co., Ltd., has become a significant player in the domestic skincare market, achieving over 2 billion yuan in revenue for 2024, with a net profit of 129 million yuan [1]. - The brand has rapidly grown since its establishment in 2019, becoming one of the top ten domestic skincare brands in China within just seven years [5]. - HBN's growth is attributed to its strategic positioning in high-tech, low-penetration, and high-growth segments of the skincare market, focusing on key efficacy areas such as anti-wrinkle and brightening products [5]. Group 2: Market Dynamics - The shift of consumer traffic to online platforms due to macroeconomic changes has provided an opportunity for domestic beauty brands to outperform international giants [7]. - Hujia Technology has heavily invested in online channels, with nearly 100% of its revenue coming from online sales in 2024 and the first three quarters of 2025 [8]. - The success of other domestic brands, such as Perlay and Betaini, highlights a broader trend of domestic beauty brands leveraging online channels to gain market share [10][11]. Group 3: Financial Performance - Hujia Technology's revenue growth for 2024 is projected at only 6.93%, significantly below the industry median growth rate of over 21% [15]. - The company has incurred substantial marketing costs, with sales expenses amounting to 1.238 billion yuan and 871 million yuan for 2024 and the first three quarters of 2025, respectively, representing over 50% of its revenue [14]. Group 4: Challenges and Strategies - As online growth slows, Hujia Technology is exploring offline channels to drive revenue, with offline sales reaching 75 million yuan in the first three quarters of 2025, a 150% increase year-on-year [19]. - The company faces challenges in managing price discrepancies between online and offline channels, which could hinder its ability to expand offline effectively [21][22]. - Successfully integrating online and offline strategies is crucial for HBN to transition from a "viral" brand to a sustainable long-term player in the market [26].

Core Viewpoint - HBN, a popular domestic skincare brand, is set to go public, aiming to become "China's first effective skincare stock" [1]. Company Overview - HBN is recognized as a leading dermatological skincare brand in China and is one of the first domestic brands to propose the "Morning C, Evening A" skincare concept [2]. - According to ZhiShi Consulting, HBN is the youngest among the top ten domestic skincare brands in China by retail sales in 2024 and is the largest domestic brand in the improving skincare market [2]. Founder Background - The founder, Yao Zhenan, is an 80s generation entrepreneur who studied in the UK and has a background in design and animation [4][5]. - Yao Zhenan has been a lecturer and graduate advisor at Shenzhen University from 2009 to 2023 while also founding HBN [5][6]. Business Evolution - HBN was established after Yao Zhenan pivoted from a previous venture in women's care products to focus on effective skincare in 2019 [7][8]. - The brand quickly gained market traction by launching products like retinol serums and α-arbutin essence, leveraging the rise of live-stream e-commerce [9]. Financial Performance - The company's total revenue increased from RMB 1.949 billion in 2023 to RMB 2.083 billion in 2024, marking a 6.9% growth [10]. - Net profit surged by 232.5% from RMB 0.388 billion in 2023 to RMB 1.291 billion in 2024, with net profit margins rising from 1.9% to 6.2% [11]. - Adjusted net profits for 2023, 2024, and the first three quarters of 2025 were RMB 0.923 billion, RMB 1.294 billion, and RMB 1.453 billion, respectively [11]. Product Contribution - The majority of revenue comes from improving skincare products, accounting for 81.8%, 78.3%, and 78.6% of total revenue in the respective years [11]. - Gross profit for 2023, 2024, and the first three quarters of 2025 was RMB 14.93 billion, RMB 15.30 billion, and RMB 11.39 billion, with gross margins of 76.6%, 73.4%, and 75.3% [12]. Strategic Partnerships - Meitu, a significant shareholder, plays a crucial role in HBN's growth by providing advantages in traffic and brand operation [13][15]. - Meitu's investment in HBN aligns with its strategic transformation and has contributed to its profitability, with a reported fair value gain from investments between RMB 4.85 billion and RMB 5.65 billion in 2022 [16]. Shareholding Structure - Prior to the IPO, Yao Zhenan holds 35.08% of the shares, his wife holds 13.6%, and Meitu is the largest institutional shareholder with 23.81% [18].

Core Viewpoint - The company, Shenzhen Hujia Technology (Group) Co., Ltd., has submitted its IPO application to the Hong Kong Stock Exchange, showcasing its strong position in the Chinese skincare market with its core brand HBN and a focus on the "early C, late A" skincare philosophy [1]. Group 1: Company Overview - Hujia Technology has established itself as a leading domestic brand in the Chinese skincare market, particularly in the improvement skincare segment, and is recognized for its strong research background [1]. - The company ranks among the top ten domestic skincare brands in China by retail sales for 2024, and it is the youngest brand in this category [1]. - Hujia's A-retinol products have been the best-selling in the Chinese market for three consecutive years, and its star product, α-arbutin essence water, has also achieved top sales in its category [1]. Group 2: Financial Performance - The company's revenue is projected to grow by 6.9% in 2024 and by 10.2% in the first nine months of 2025, indicating a relatively slow growth rate [2]. - In 2023, the total revenue was approximately 1.95 billion RMB, with a gross profit margin of 76.6% [3]. - The net profit margin improved significantly from 1.9% in 2023 to 9.6% in the first nine months of 2025, primarily due to cost control rather than strong revenue growth [3][4]. Group 3: Operational Risks - The company heavily relies on its single brand HBN, which contributed 78.6% of its revenue and 74.5% of its gross profit in the first nine months of 2025, indicating a concentration risk [6]. - Hujia's sales are predominantly online, with 95.1% of revenue coming from online channels, which ties the company's performance closely to the dynamics of e-commerce platforms [7]. - The company faces challenges in expanding its offline presence, as its offline revenue is currently less than 5%, requiring significant capital investment and time to develop [7]. Group 4: Supply Chain and Cash Flow Concerns - The company has a high dependency on its top five suppliers, which account for 46% of its procurement, posing risks to production and cost stability [8]. - The cash flow management shows structural issues, with a net cash flow from operating activities of only 1.56 billion RMB in 2024, indicating low cash conversion efficiency [4][5]. - Inventory turnover days have increased from 105 to 130 days, suggesting potential issues with product movement and increased risk of inventory obsolescence [8]. Group 5: Future Challenges - The company must address how to overcome the limitations of its single brand strategy and achieve sustainable growth in a competitive market [9]. - There is a need to optimize supply chain management and improve cash flow quality to ensure long-term financial stability [9]. - The challenge of establishing a profitable model in the offline market while managing high operational costs remains a critical focus for the company [9].

Core Viewpoint - The recent IPO submission by Shenzhen Hujia Technology (Group) Co., Ltd. (HBN) highlights the growth potential of domestic beauty brands in China, showcasing simultaneous revenue and profit growth while revealing structural challenges in the industry, such as high marketing costs and heavy reliance on online sales channels [1][2]. Financial Performance - HBN's revenue for 2023 and 2024 is projected to be 1.95 billion and 2.08 billion yuan, respectively, with year-on-year growth rates of approximately 6.9%. For the first nine months of 2024 and the same period in 2025, revenue is expected to be 1.37 billion and 1.51 billion yuan, reflecting a year-on-year growth of 10.2% [1]. - Net profit is forecasted to be 38.8 million yuan in 2023 and 130 million yuan in 2024, with a staggering year-on-year growth of 232.5%. For the first nine months of 2024 and 2025, net profit is expected to be 49.8 million and 140 million yuan, showing a year-on-year increase of 190.3% [1][2]. - The net profit margin is steadily increasing from 1.9% in 2023 to 9.6% in the first nine months of 2025, while the gross profit margin remains stable at around 75%, which is relatively high compared to industry averages [2]. Marketing and Sales Strategy - HBN's marketing and distribution expenses accounted for 65.1%, 59.4%, 61.8%, and 57.6% of total revenue in 2023, 2024, and the first nine months of 2024 and 2025, respectively. Promotion expenses constitute a significant portion of these costs, indicating that nearly half of the company's revenue is spent on marketing [3]. - Online channels contributed to 98.6% and 97.7% of total revenue in 2023 and 2024, with projections of 97.8% and 95.1% for the first nine months of 2024 and 2025, demonstrating a heavy reliance on online sales for revenue generation [3][4]. Corporate Governance and Control - The control of HBN is highly concentrated, with the founders holding 76.19% of voting rights, and their combined shareholding is 48.68%. This concentration raises questions about governance and the implications of a significant pre-IPO cash dividend of 100 million yuan, of which nearly half will likely benefit the founders [5][6]. - The company plans to selectively expand its offline sales channels to diversify its market presence and enhance consumer engagement, although its offline business remains limited at present [4]. Industry Trends - The trend of domestic beauty brands going public in Hong Kong is on the rise, with several companies completing IPOs or in the process since late 2024. This trend is attributed to stricter A-share regulations and a more favorable environment in Hong Kong for capital raising [6][7]. - Factors influencing this shift include regulatory changes, the need for flexible financing options, and the pursuit of internationalization, making Hong Kong a more attractive market for these beauty brands [7][8].

Group 1 - HBN's parent company, Shenzhen Hujia Technology (Group) Co., Ltd., submitted a listing application to the Hong Kong Stock Exchange on January 26, with Meitu as a significant shareholder holding 23.81% [2] - HBN, founded in 2019, focuses on skincare products with a pricing range of 129 to 689 yuan, promoting the "morning C, evening A" skincare concept [2] - Meitu's investment in HBN began in 2020, as part of a strategic transformation plan to enter the social sector amid increasing competition [2][3] Group 2 - Meitu reported a turnaround in profitability in 2022, largely attributed to the fair value gains from its investment in HBN, estimated between 485 million to 565 million yuan [3] - HBN's shareholding structure changed, with Meitu's stake decreasing from 28.2% to 23.81% due to share transfers and capital increases, while the largest shareholders are now Yao Zhenan (35.08%) and Wang Yang (13.6%) [3] - HBN's revenue for 2023, 2024, and the first three quarters of 2025 is projected at 1.948 billion, 2.083 billion, and 1.514 billion yuan, respectively, with net profits of 39 million, 129 million, and 145 million yuan, maintaining a gross margin of 73% to 77% [3] Group 3 - On the same day HBN submitted its listing application, Meitu acknowledged the move and expressed intent to continue holding its stake in HBN, citing potential synergies between their beauty businesses [4]

Core Viewpoint - HBN, a domestic skincare brand, has submitted its IPO application to the Hong Kong Stock Exchange, aiming to expand its market presence and enhance product innovation [1]. Financial Performance - HBN's revenue for 2023, 2024, and the first nine months of 2025 is projected to be CNY 19.48 billion, CNY 20.83 billion, and CNY 15.14 billion, respectively, with a year-on-year growth of 6.9% in 2024 and 10.2% in the first nine months of 2025 [1][2]. - Net profit for the same periods is expected to be CNY 0.39 billion, CNY 1.29 billion, and CNY 1.45 billion, showing a significant increase of 232.5% in 2024 and 190.3% in the first nine months of 2025, with net profit margin rising from 1.9% to 9.6% [1][2]. Product Lines - HBN offers a range of skincare products, including anti-aging, brightening, repairing, and basic skincare lines, with a total of 36 SKUs available by September 30, 2025 [1]. - The core business of improvement-type skincare products generated revenues of CNY 15.94 billion, CNY 16.31 billion, and CNY 11.90 billion for the years 2023, 2024, and the first nine months of 2025, with gross margins of 76.4%, 72.4%, and 74.5%, respectively [2][3]. Sales Channels - Online sales remain the primary revenue source, accounting for over 95% of total revenue from 2023 to the first nine months of 2025, with revenues of CNY 19.20 billion, CNY 20.34 billion, and CNY 14.39 billion [3]. - Offline sales are emerging as a new growth area, with revenues increasing from CNY 0.28 billion in 2023 to CNY 0.75 billion in the first nine months of 2025, raising its share from 1.4% to 4.9% [3]. Marketing and R&D Expenditure - Sales and distribution expenses for 2023 and 2024 were CNY 12.67 billion and CNY 12.38 billion, representing 65.1% and 59.4% of total revenue, respectively [4]. - R&D expenditures have decreased, with amounts of CNY 0.66 billion, CNY 0.58 billion, and CNY 0.40 billion for 2023, 2024, and the first nine months of 2025, accounting for 3.4%, 2.8%, and 2.6% of total revenue [4]. - The IPO proceeds will be directed towards R&D, product innovation, capacity upgrades, digital operations, and multi-channel expansion [4].

Group 1 - The core viewpoint of the article is that HBN, a domestic skincare brand, has submitted an IPO application in Hong Kong, aiming to become the first stock in the "true efficacy skincare" segment in China [2] - HBN was founded in 2019 with a focus on efficacy-driven skincare products and has ranked among the top ten domestic skincare brands in China by retail sales as of 2024 [5] - The brand has established market recognition in core efficacy ingredients and has been a pioneer in promoting the "morning C, evening A" skincare concept, achieving leading domestic sales in its product categories for three consecutive years from 2022 to 2024 [5] Group 2 - HBN has experienced rapid growth, with projected total revenue of 2.08 billion RMB for 2024 and a 10.2% year-on-year increase in revenue for the first three quarters of 2025, reaching 1.51 billion RMB [7] - The adjusted net profit is expected to grow from 90 million RMB in 2023 to 130 million RMB in 2024, further increasing to 150 million RMB in the first three quarters of 2025, with the adjusted net profit margin rising from 4.7% in 2023 to 9.6% in the first three quarters of 2025 [7] - The Chinese dermatological skincare market is one of the fastest-growing segments, with a compound annual growth rate exceeding 16.7% from 2019 to 2024, and HBN aims to leverage international capital markets for long-term development and to unlock growth potential in the efficacy skincare sector [7]

Company Overview - Shenzhen Hujia Technology (Group) Co., Ltd. is a leading skincare brand in China, focusing on improvement-type skincare products and is one of the first domestic brands to propose the "Early C, Late A" skincare concept [1][3] - The HBN brand, launched in 2019, aims to meet the growing consumer demand for scientifically proven skincare efficacy, offering products for anti-wrinkle, firming, and brightening [3] - As of September 30, 2025, HBN will have 36 SKUs available, catering to various skin types and needs [3] - Hujia Technology has become the largest domestic skincare brand in the improvement-type skincare market and a leading brand in A-retinol skincare products in China [3] Research and Development - The company invests continuously in R&D to drive innovation in skincare products, focusing on skin physiology, active ingredients, innovative formulations, and advanced delivery technologies [4] - Hujia Technology has published the highest number of papers as the first author in SCI-indexed journals among domestic skincare brands [4] - The company has developed China's first A-retinol synthetic ingredient approved for new cosmetic raw material registration and is a leader in peptide research [4] Financial Performance - For the fiscal year ending December 31, 2023, the company reported revenues of approximately RMB 1.948 billion, with a gross profit of RMB 1.493 billion, resulting in a gross margin of 76.6% [5][8] - The net profit for the same period was approximately RMB 38.8 million [6] - The company expects revenues of RMB 2.083 billion for the fiscal year 2024, with a projected net profit of RMB 129.1 million [5][6] Industry Overview - China's cosmetics market is one of the largest globally, with a market size growing from RMB 531.1 billion in 2019 to an estimated RMB 688.6 billion by 2024, reflecting a compound annual growth rate (CAGR) of 5.3% [9] - Despite steady growth, per capita cosmetics spending in China remains significantly lower than in the US and Europe, indicating substantial growth potential [9] - The mid-to-high-end skincare segment is experiencing rapid growth, with its market size projected to increase from RMB 156 billion in 2019 to RMB 254.2 billion by 2024, at a CAGR of 10.3% [12]

Core Insights - L'Oréal Group announced the acquisition of a majority stake in the UK skincare brand Medik8 for approximately €1 billion, expected to be completed in the coming months [1] - Medik8 will enhance L'Oréal's luxury cosmetics division, indicating a trend towards high-end efficacy skincare [1] - Medik8, founded in 2004 by Elliot Isaacs, is known for its CSA skincare system and has a strong emphasis on ingredient-driven formulations [7] Company Overview - Medik8 has developed a diverse omnichannel sales model, covering major online and offline retail channels in Europe and expanding its influence in the US market [8] - The brand has participated in major beauty expos in China, indicating interest in entering the Chinese market, although it has faced challenges in establishing a presence [11] - In the 12 months ending September 2023, Medik8 reported revenues of £45.3 million and a pre-tax profit of £15.6 million, with projected global sales reaching $115 million for the year [11] Product and Brand Strategy - Medik8 emphasizes a "science-led" approach, supported by a team of experts in biochemistry and dermatology, and holds several proprietary technologies [7] - The brand's flagship product, Crystal Retinal, is priced between €56 and €135, aligning it with luxury skincare pricing [1] - Following the acquisition, Isaacs will remain on the board to ensure operational stability, while private equity firm Inflexion retains a minority stake [11]

Group 1 - L'Oréal Group is currently the most competitive acquirer in the potential acquisition of the UK skincare brand Medik8, although both parties have not commented on the rumors [1][2] - Medik8 was founded in 2004 by pharmacologist and biochemist Elliot Isaacs, who introduced the CSA skincare philosophy, which emphasizes using Vitamin C and sunscreen during the day and Vitamin A at night [2][3] - Medik8's sales are projected to grow by 50% in 2024, with expected global revenue reaching approximately $115 million (around 833 million RMB) in 2025, and the brand operates in over 25 countries with products sold in more than 7,000 beauty salons [2][3] Group 2 - Medik8's website has seen a monthly average of over 100,000 visits in 2024, with a 90% year-on-year increase in unique visitors, ranking first in the UK beauty and health website traffic [3] - The brand's parent company, Pangaea Laboratories, received investment from private equity fund Inflection Buyout Fund V in 2021, although the specific amount was not disclosed [3] - Despite its growth, Medik8 currently lacks official online sales channels in China, with its official public account inactive since May 2021 [4] Group 3 - The skincare science sector is becoming increasingly competitive, with L'Oréal Group focusing on expanding its presence in this area through acquisitions and investments [6][8] - In 2024, L'Oréal's skincare division achieved sales of €7.027 billion (approximately 53.241 billion RMB), marking a 9.8% year-on-year increase, making it the fastest-growing segment for the company [6][7] - The global market for adult dermatological skincare products reached $2.295 billion (approximately 16.539 billion RMB) in 2023, with projections to grow to $4.687 billion (approximately 33.777 billion RMB) by 2030, reflecting a compound annual growth rate (CAGR) of 12.3% from 2024 to 2030 [8]